Capecitabine Tablet, Film Coated
Product Images NDC 62756-239

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 62756-239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mglabel (150mglabel)

Capecitabine Tablets, USP 150 mg film-coated tablets packaging label from Sun Pharmaceutical Industries, Inc. The label shows a 60 tablet count, with the NDC number 62756-238-86, and a barcode. The design includes a yellow highlight behind the strength dose information.*

FDA Label Image

500mglabel (500mglabel)

Label for Capecitabine Tablets, USP 500 mg film-coated tablets by Sun Pharmaceutical Industries, Inc. The label indicates the prescription drug contains 30 tablets. The NDC number is 62756-239-83 with a barcode and a note to open for full labeling.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of Capecitabine, showing its molecular components and arrangement including a fluorinated pyrimidine and sugar moiety with an attached ester group.*

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve chart comparing disease-free survival between two treatment groups: 5-FU with Leucovorin and Capecitabine over 96 months since randomization. The y-axis shows survival probability from 0 to 1, and the x-axis shows months. Below the x-axis, numbers at risk for each group are listed at various time points.*

FDA Label Image

Figure2 (Figure2)

Kaplan-Meier survival curve comparing overall survival between two treatment groups: 5-FU plus leucovorin and capecitabine. The x-axis represents months since randomization, extending to 96 months, and the y-axis represents survival probability from 0 to 1. The graph includes the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure3 (Figure3)

Kaplan-Meier curve displaying overall survival probabilities over time (days) for pooled data from two studies comparing treatment groups: 5-FU plus Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The y-axis shows estimated survival probability, and the x-axis represents days of follow-up, reaching up to 1500 days.*

FDA Label Image

Figure4 (Figure4)

Kaplan-Meier estimate graph comparing time to disease progression between two groups: one treated with Docetaxel 100 mg/sqm every 3 weeks and the other with Capecitabine 1250 mg/sqm twice daily intermittent combined with Docetaxel 75 mg/sqm every 3 weeks. The graph shows estimated probability over time in days, illustrating disease progression rates for each treatment group.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve chart comparing estimated survival probabilities over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks versus Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The vertical axis shows estimated probability from 0 to 1; the horizontal axis shows time in days up to 800. Two vertical markers highlight times around 351.5 and 442 days.*

FDA Label Image

Formula (Formula)

The image shows a formula for calculating creatinine clearance in males. It uses variables for age in years, body weight in kilograms, and serum creatinine in mg/dL. This is a text panel related to clinical calculations and kidney function assessment.*

FDA Label Image

Formula1 (Formula1)

Illustration showing the metabolic pathway of capecitabine to 5-fluorouracil (5-FU). It depicts the chemical structures of capecitabine, 5'-DFCR, 5'-DFUR, and 5-FU, with arrows and enzymes (Carboxylesterase, Cyd deaminase, dThdPase) indicating the metabolic conversion steps.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.